CompletedInterventionalPhase 3Last updated Aug 19, 2009

Study Evaluating DVS-233 in Adult Outpatients With Major Depressive Disorder

A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of a Flexible Dose of DVS-233 SR in Adult Outpatients With Major Depressive Disorder

Overview

ClinicalTrials.gov ID: NCT00063206
Lead Sponsor: Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY
Brief Summary: Primary: To compare the antidepressant efficacy and safety of subjects receiving DVS-233 SR versus subjects receiving placebo.

Secondary: To assess the response of subjects receiving DVS-233 SR for the clinical global evaluation, functionality, general well-being, pain, and remission (Hamilton Psychiatric Rating Scale for Depression, 17-item [HAM-D<sub>17</sub>] < 7) versus those subjects receiving placebo.

Status

Overall Status: Completed
Start Date: No data available
Primary Completion Date: May 2004Actual
Completion Date: May 2004Actual

Study Record Dates

First Submitted: Jun 23, 2003
First Submitted that Met QC Criteria: Jun 24, 2003
First Posted: Jun 25, 2003Estimated
Last Update Submitted that Met QC Criteria: Aug 18, 2009
Last Update Posted: Aug 19, 2009Estimated
Last Verified: Aug 2009

NCT00073762Completed

Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder

NCT00092911Completed

Study Evaluating DVS-233 SR in Adult Outpatients With Major Depressive Disorder

NCT00072774Completed

Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder

NCT00075257Completed

Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder

NCT00090649Completed

Study Evaluating DVS-233 SR And Venlafaxine ER In Adult Outpatients With Major Depressive Disorder

NCT00087737Completed

Study Evaluating DVS-233 SR and Venlafaxine ER in Adult Outpatients With Major Depressive Disorder